Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Buse

Showing results (141-150 of 457) with videos related to

Pageof 46
Sort By:
Lancet (London, England)|June 12, 2009
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)John B Buse, Julio Rosenstock, Giorgio Sesti, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 24, 2011
Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development programRobert R Henry, John B Buse, Giorgio Sesti, et al.
Diabetes Care|August 13, 2014
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)John B Buse, Tina Vilsbøll, Jerry Thurman, et al.
Pharmacoepidemiology and Drug Safety|April 4, 2017
Differential Use of Screening Mammography in Older Women Initiating Metformin versus SulfonylureaJin-Liern Hong, Louise M Henderson, Michele Jonsson Funk, et al.
Nature|March 26, 2026
Towards intelligent and miniaturized drug delivery devicesXinwei Wei, John B Buse, Hongming Chen, et al.
Diabetes Care|July 29, 2006
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDavid M Nathan, John B Buse, Mayer B Davidson, et al.
Molecular Biosystems|February 9, 2012
Exploring salivary proteomes in edentulous patients with type 2 diabetesMichael B Border, Sarah Schwartz, Jim Carlson, et al.
Epidemiology (Cambridge, Mass.)|February 7, 2017
Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older WomenJin-Liern Hong, Michele Jonsson Funk, John B Buse, et al.
JAMA|March 3, 2016
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical TrialIldiko Lingvay, Federico Pérez Manghi, Pedro García-Hernández, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 2011
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trialsJohn B Buse, Alan Garber, Julio Rosenstock, et al.
Pageof 46

Showing results (141-150 of 457) with videos related to

Sort By:
Pageof 46
Lancet (London, England)|June 12, 2009
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)John B Buse, Julio Rosenstock, Giorgio Sesti, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 24, 2011
Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development programRobert R Henry, John B Buse, Giorgio Sesti, et al.
Diabetes Care|August 13, 2014
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)John B Buse, Tina Vilsbøll, Jerry Thurman, et al.
Pharmacoepidemiology and Drug Safety|April 4, 2017
Differential Use of Screening Mammography in Older Women Initiating Metformin versus SulfonylureaJin-Liern Hong, Louise M Henderson, Michele Jonsson Funk, et al.
Nature|March 26, 2026
Towards intelligent and miniaturized drug delivery devicesXinwei Wei, John B Buse, Hongming Chen, et al.
Diabetes Care|July 29, 2006
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDavid M Nathan, John B Buse, Mayer B Davidson, et al.
Molecular Biosystems|February 9, 2012
Exploring salivary proteomes in edentulous patients with type 2 diabetesMichael B Border, Sarah Schwartz, Jim Carlson, et al.
Epidemiology (Cambridge, Mass.)|February 7, 2017
Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older WomenJin-Liern Hong, Michele Jonsson Funk, John B Buse, et al.
JAMA|March 3, 2016
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical TrialIldiko Lingvay, Federico Pérez Manghi, Pedro García-Hernández, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 2011
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trialsJohn B Buse, Alan Garber, Julio Rosenstock, et al.
Pageof 46